Drugs / Lu AF11167
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04104503 | Sep 2019 → Apr 2020 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02260830 | Aug 2014 → Mar 2015 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02199431 | Jul 2014 → Feb 2015 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02202213 | Oct 2013 → Feb 2015 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03929497 | Apr 2019 → Sep 2020 | schizophrenia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 2 | NCT03793712 | Dec 2018 → Aug 2020 | schizophrenia | H. Lundbeck A/S | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AF11167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03929497 ↗ |
| Action | Inhibit | “Lu AF11167 is a selective, high-affinity inhibitor of PDE10A” PMID 35704951 ↗ Jun 2022 |
| Route | Oral | “single oral dose of Lu AF11167” NCT02199431 ↗ |
| Target | PDE10A | “Lu AF11167 is a selective, high-affinity inhibitor of PDE10A” PMID 35704951 ↗ Jun 2022 |